The objective of this study was to compare the changes on bone mineral density, and the eVects on persistence and adverse events in patients treated for postmenopausal osteoporosis with generic alendronate or with branded alendronate (Fosamax ® ) or branded risedronate (Actonel ® ) once weekly. In this retrospective patient chart analysis, we reviewed the 1-year observational treatment results for 186 women (ITT population) with postmenopausal osteoporosis. Patients from our outpatient department, who had started with once-weekly bisphosphonate therapy between 36 and at least 12 months before this chart review, were included in this comparative three-arm study according to their treatment: A, Generic Alendonate 70 mg products; B, Branded Alendronate (Fosamax ® ) 70 mg once weekly and C, Branded Risedronate (Actonel ® ) 35 mg once weekly. All patients received basic therapy with 1,200 mg calcium and 800 IU vitamin D per day. Patient's bone mineral density (BMD) at lumbar spine and total hip was below ¡2.5 T-score, and they were with or without prevalent vertebral and non-vertebral fractures. Data analysis regarding the 186 patients shows an average increase in LS-BMD after 12 months of 2.8, 5.2 and 4.8% for the groups A, B and C, respectively. The respective mean changes at total hip were 1.5, 2.9, and 3.1%. At both sites, the mean increases in BMD were not diVerent between the two groups receiving branded bisphosphonates (B, C) but for both were signiWcantly higher than for the group treated with generic alendronate (A). At 12 months, 68% of group A, 84% of group B and 94% of group C were still on bisphosphonate therapy. The persistence of patients treated with generic alendronate was signiWcantly lower as compared to each of the two with branded bisphosphonate-treated groups. The total numbers of patients reporting gastrointestinal adverse events were 32, 15 and 9 for group A, group B, and group C, respectively. SigniWcantly lower increases of lumbar spine and total hip BMD with generic alendronate once weekly as compared to the two branded bisphosphonate originals (Fosamax ® , Actonel ® ) were observed. The reasons for the 40-50% lower BMD increase rates when using the generic compounds are not known yet. At least in part the lower eYcacy can be explained by a signiWcantly lower degree of persistence with generic alendronate, which could be related to a higher incidence of gastrointestinal adverse events. Other reasons could be lower bioavailability or potency of generic alendronate.
Introduction

Osteoporosis is an important and very frequent chronic disease
Osteoporosis is a very common skeletal disease in aging populations and accordingly listed by the WHO and UNO among the ten most important and most frequent chronic diseases of mankind [1, 2] . It is a progressive skeletal pathology characterized by loss of bone mass and quality and development of brittle bones that results in increased risk of fractures. The estimated worldwide number of new osteoporotic fractures for the year 2000 was 9.0 million, of which 1.6 million were at the hip, 1.7 million were at the distal forearm and 1.4 million were clinical vertebral fractures [3] . Osteoporotic fractures have extensive clinical and economic consequences, and are a major public health concern. The important burden of osteoporotic fractures highlights the need for osteoporosis therapies with established high eYcacy.
Bisphosphonates are the most common therapy for osteoporosis Treatment options for osteoporosis have substantially improved in recent years [1, 2, [4] [5] [6] : appropriate antiresorptive or anabolic medications are available to prevent future fractures. Bisphosphonates inhibit osteoclast activity. Bisphosphonates are today's worldwide leading medication [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] and are recommended as Wrst-line treatment for osteoporosis [1, 2, 17, 18] . Two chemically distinct groups of bisphosphonates exist: simple non-nitrogen-containing bisphosphonates (Non-N-BP's, e.g., Etidronate) and nitrogen-containing bisphosphonates (N-BP's), e.g., Ibandronate, Alendronate, Zoledronate, and Risedronate. There are two fundamentally distinct components of the mechanism of action of nitrogen-containing bisphosphonates (N-BPs) [19, 20] : These are (1) binding to the bone, and (2) binding to and inhibition of a key osteoclast enzyme farnesyl pyrophosphate synthase (FPPS). Regarding the oral bisphosphonates, only Risedronate and Alendronate have been proven to reduce vertebral and hip fracture risk in clinical trials [8] [9] [10] [11] [12] [13] [14] [15] [21] [22] [23] [24] . Zoledronate is an intravenous bisphosphonate therapy and has also been proven to reduce vertebral and hip fracture risk in clinical trials.
The importance of compliance, persistence and adherence for optimal therapeutic results
The therapeutic aim of reducing the risk of fractures requests a persistent intake of an eVective long-term medication [1, 2] . The eVectiveness of a treatment, however, depends not only on the eYcacy of the used medication but also on persistent drug intake of patients [25] [26] [27] [28] . Drugs do not work in patients who do not take them. Compliance is basically adherence to a drug regimen as in taking medications correctly and on time. It can be deWned as the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen. Compliance is usually measured over a period of time and reported as a percentage [29] . Compliance diVers from persistence, which is deWned as the duration of time from initiation to discontinuation of therapy. Persistence indicates how long a patient remains on therapy and it ends as soon as a patient stops taking a speciWed drug for a prolonged period of time. Adherence is the combination of compliance and persistence. Compliance, persistence and adherence are also crucial to achieve the optimal therapeutic results in patients' real daily life situation as demonstrated in clinical trials.
Introduction of generic bisphosphonates
During the past years an increasing number of generic alendronates were introduced, based on bioequivalence data, in numerous countries. Insurances and Health Care Providers increased pressure on physicians to prescribe mainly generic alendronate instead of branded original bisphosphonates like Fosamax ® (Alendronate) and Actonel ® (Risedronate). Little is known, however, about the provenience and quality of the still increasing number of generic Alendronates, and clinical trials or observational postmarketing studies on bone mineral density and fracture eYcacy, adverse events and compliance or persistence with these new "Alendronic acids" initiatives were never performed. This is an important gap of knowledge and means today physicians in many countries are supposed to prescribe mainly these cheaper generic Alendronates and at the same time they are unaware of the manufacturer of the respective compounds and whether eYcacy and safety are really the same as were demonstrated for the original branded oral bisphosphonates in clinical or real practice studies. Also a higher rate of adverse events with generic Alendronates has often related from daily practice but only one study from Canada was published demonstrating, indeed, a higher incidence in gastro-intestinal side eVects in patients treated with generic alendronate as compared to those treated with original once weekly bisphosphonates [30] . Another major concern about these new "Alendronic acids" seems to be also the reduced medication compliance in clinical practice. An additional issue is related to the major disadvantage of the clinically utilized oral bisphosphonates which is their poor oral absorption from the gastrointestinal tract: typically less than 1% is absorbed. The poor absorption of bisphosphonates is most likely due to their very poor lipophilicity and charge, which prevents transcellular transport across the epithelial barriers. The question arises whether the absorption of generic alendronates, and thus its bioavailability, is further altered because of the variation in galenic/tablet properties. This can potentially aVect the clinical outcome when used in the treatment of osteoporosis. 
Patients and study design
In this retrospective patient data analysis, we reviewed clinical records of 204 women (50 years of age and older) with postmenopausal osteoporosis for relevant standard patient baseline data and for 1-year observational treatment results using a standardized patient chart data entry sheet. Patients were eligible for this review, from Wles of our out-patient department, if they were above 50 years of age and had initial BMD T-score values lower than ¡2.5 SD at lumbar spine (LS) and lower than ¡2.0 SD at the total hip (TH) with or without prevalent vertebral fractures. All participants gave verbal consent to participate in this retrospective patient data analysis. The study was approved by the local Hospital Research Ethics Committee. Selected patients were either without any pre-treatment or with diVerent previous treatments except bisphosphonates (e.g., HRT, raloxifen, tibolone, calcitonin, alfacalcidol, calcium, plain vitamin D). They had started with a once-weekly bisphophonate therapy between 3 years and 1 year before this evaluation and were allocated consecutively, according to their treatment to join one of three arms: (A) Generic alendonate 70 mg once a week, (B) Alendronate (Fosamax ® ) 70 mg once a week and (C) Risedronate (Actonel ® ) 35 mg once a week. A further selection criterion was initial prescription of 1,200 mg calcium and 800 IU vitamin D per day. BMD DXA-measurements (GE Lunar Prodigy™ DXA Bone Densitometer) and lateral vertebral morphometry (LVA, GE Lunar Prodigy™) or X-rays from thoracic and lumbar spine had to be performed at baseline and after 12 months. Patients of all three groups were excluded if they had been switched to another speciWc drug therapy (non-bisphosphonates) during the 1 year of follow-up. Switching to a generic or another branded original bisphosphonate in group B or C during the 1 year of observation was an exclusion criterion, while in group A switching from one to another generic alendronate was allowed. Not all information about the frequency of switching generic alendronates in group A and on the respective manufactures was available in the patient charts. In Table 1 the initial characteristics of the 186 patients who fulWlled all above criteria are given. To assess patients' persistence patients were asked using a standardized semi-structured questionnaire during the routine follow-up visit at month 12 how long they remained on therapy (calcium, vitamin D and/or and/or branded or generic bisphosphonate once a week) and when they stopped taking their osteoporosis drug (calcium, vitamin D and/or and/or branded or generic bisphosphonate once a week) for a prolonged period of time. Also during the routine follow-up visit at month 12 patients were asked how they take their drug regimen. Compliance was determined asking the patient how they took their osteoporosis medication and if they took it on time. Patient's verbal feedback regarding compliance and persistence was rated and coded in the clinical record.
Statistical methods
One hundred and eighty six of the 204 women with postmenopausal osteoporosis who fulWlled the inclusion criteria were included in the retrospective patient data analysis. Baseline characteristics were summarized using descriptive statistics. Formal statistical modeling was performed using SAS Version 9.1. All statistical tests were two-sided at the 5% level of signiWcance. Table 2 shows the numbers and percentages of patients still on bisphosphonate therapy and on calcium/vitamin D supplementation after 12 months and the average months of intake for the three treatment groups. Still on their respective BP-therapies were 68% of group A (Generic Alendonate 70 mg products), 84% of group B [Branded Alendronate (Fosamax ® ) 70 mg] and 94% of group C [Branded Risedronate (Actonel ® ) 35 mg]. The persistence of patients treated with Generic Alendonate 70-mg products was signiWcantly lower as compared to each of the two original branded BP treated groups (Fig. 1) . Corresponding to these Wndings the persistence with calcium vitamin D supplementation was also lower in group A than in groups B and C. (Table 3 ). The prevalence of gastrointestinal adverse events was signiWcantly higher in Group A. Other non-gastrointestinal AEs were observed in 14 patients of group A, 9 and 5 respectively in groups B and C ( (Fig. 2) . The respective mean changes at the total hip site were 1.5, 2.9, and 3.1%. At both sites the mean increases in BMD were not diVerent between the two groups receiving original branded BP's (B, C) but for both signiWcantly higher than for group A treated with generic Alendonate 70-mg products (Fig. 2) .
Results
Persistence
Discussion
The total number of patients reporting gastrointestinal events was signiWcantly higher in patients treated with generic Alendonate 70 mg once-weekly products than with the two branded original bisphosphonate-treated patients. Data analysis shows after 12 months signiWcantly higher average BMD increases at lumbar spine and at total hip for 
All GI adverse events 32* 15 9 ) treatment at the lumbar spine were 86 and 71% higher, respectively, and at the proximal femur 93 and 107%, respectively (Fig. 2) . In our study the persistence of patients treated with generic Alendonate 70 mg once weekly products was signiWcantly lower as compared to each of the two with branded original bisphosphonatetreated patient groups.
What could be possible explanations for these signiWcant diVerences in the therapeutic response?
1. Smaller increases in BMD due to lower persistence as a consequence of a higher rate of adverse events? 2. Lower bioavailability and higher rate of adverse events due to diVerences in disintegration and dissolution properties and esophageal transit time of tablets? 3. Smaller increases in BMD due a false intake of generic alendronate? 4. Smaller increases in BMD due to lower persistence as a consequence of additional psychological factors? 5. A combination of any of the previous four-ones?
Smaller increases in BMD due to lower persistence as a consequence of a higher rate of adverse events Since a signiWcantly lower persistence with generic bisphosphonates was shown in our study (Fig. 1) , this may be indeed the major factor leading to the highly signiWcant lower increases in BMD at both measuring sites. DiVerent studies in recent years proved signiWcant correlations between compliance and therapeutic results during bisphosphonate therapy [26, 34, 35] . It was shown that noncompliance with antiresorptive therapies has been associated with a 16-50% increased risk of fracture [26, [34] [35] [36] [37] [38] . Also it was proven that subgroups with good compliance with bisphosphonates (e.g., over 80%) had higher increases in bone mineral density (BMD) and a signiWcantly stronger eVect on fracture risk than those with poor compliance [26, 27, 37] .
Lower bioavailability and higher rate of adverse events due to diVerences in disintegration and dissolution properties and esophageal transit time of tablets
The lower persistence in patients treated with Generic Alendronate 70 mg (and Generic Alendronate 70 mg) once weekly products which was shown in our study could be explained by the higher rates of gastrointestinal adverse events (Table 3 ). There exists some evidence that branded Risedronate might be a slightly better suitable alternative bisphosphonate drug for gastrointestinal-sensitive patients compared to original branded or generic alendronate [7-9, 32, 33, 39-46] . Two recent studies have shown diVerences in tablets' properties that might explain diVerent rates of adverse events. An in vitro study compared the disintegration and dissolution of once weekly original branded Risedronate (Actonel ® ) and original branded Alendronate (Fosamax ® ) tablets with 26 diVerent Generic Alendronate copies from Canada, Germany, the Netherlands, and UK [47] . The mean disintegration times of the generic alendronate tablets in vitro ranged from 14 to 342 s (5.7 min) [47] . The mean disintegration time of the branded product tablets (Actonel ® and Fosamax ® ) ranged only from 43 to 78 s [47] . Six of the 26 companies market alendronic acid tablets having very rapid disintegration times which are similar to those of orally disintegrating tablets (non-bisphosphonates) [47] . Since there is no established disintegration time for Alendronate tablets, there can be no assurance that the Generic Alendronate copy tablets are equivalent to the branded product in terms of esophageal drug exposure [47] .
Another trial evaluated and compared esophageal transit times and in vivo disintegration of one branded risedronate and two generic formulations of alendronic acid tablets [48] that are commercially available in Canada and the United Kingdom. It was shown that the two generic formulations of ) tablet tested [48] . The branded risedronate tablet had a signiWcantly faster transit time than the two generic formulations of alendronate tested [48] . This is of importance for patients because delayed esophageal transit or disintegration of oral bisphosphonate tablets before they enter the stomach could cause iatrogenic complications. DiVerent formulations of generic bisphosphonate tablets meeting regulatory requirements may have substantial diVerences in pharmaceutical attributes from the branded product that may result in diVerent characteristics during esophageal transit. A potential concern is that the pharmaceutical attributes of the various copy alendronate formulations may aVect the potential for local irritation and tolerability, especially in the upper gastrointestinal tract. Epstein et al. [49] showed a greater irritant response from a copy Alendronate tablet (Novo-Alendronate 10 mg) in a rabbit injection study and in a dog esophageal study (Alendronate Sodium Tablets, Teva Industries, PetahTikva, Israel) compared to the branded innovator product (Alendronate sodium tablets, 10 mg). The diVerences were attributed to the pharmaceutical preparation, since the active ingredient (Alendronate sodium) and the dose were similar between the copy Alendronate tablets and the branded tablets. The same authors [50] also evaluated the disintegration and dissolution proWles of 13 copy Alendronate tablets available in Latin America. From a safety perspective, the authors concluded that for the rapidly disintegrating formulations there is a chance that disintegration may occur in the mouth and/or the esophagus during swallowing of the tablet. This could increase the duration and extent of oral and esophageal tissue exposed to semi-particulate alendronate and thereby increase the risk of serious mucosal irritation and ulceration [50] . From an eYcacy perspective, Epstein et al. also concluded that tablets that disintegrate faster than branded Alendronate sodium tablets (1.4 min) could result in reduced eYcacy because the premature disintegration may be associated with semi-particulate Alendronate being retained within the esophagus, increasing the likelihood of contact with ingested food, saliva, mucus or liquids, thereby reducing the bioavailability or altering the pharmacokinetics. The bioavailability and therefore the eYcacy of some generic Alendronate products due to very short disintegration times of the tablets (and a signiWcant slower esophageal transit time of Generic Alendronate tablets) could be reduced. Generic Alendronate tablets with very short disintegration times start to disintegrate very quickly already in the mouth and esophagus. The already low intestinal absorption rates of these generic bisphosphonate drugs could be further decreased and full eYcacy in terms of BMD increases not reached. The diVerence in the gastrointestinal safety and tolerability proWle in favor for Risedronate versus Alendronate could together with the inferior disintegration and dissolution characteristics and signiWcant slower esophageal transit time of once weekly generic Alendronate tablets explain the higher rates of gastrointestinal adverse events and lower eYcacy detected in patients treated with Generic Alendronate in our study. Higher rates of gastrointestinal adverse events could have implications on persistence for patients which could lead to smaller increases in BMD. All together the described inferior gastrointestinal safety and tolerability proWle of Alendronate compared to Risedronate would become even worse due to diVerences in disintegration and dissolution properties and a signiWcant slower esophageal transit time of Generic Alendronate tablets. This could due to the higher rates of gastrointestinal adverse events (Table 3 ) and lower bioavailability have implications on persistence and on eYcacy for patients which could lead to smaller increases in BMD.
Smaller increases in BMD due a false intake of generic Alendronate A prerequisite of good therapeutic results in osteoporosis with the oral N-BP's like Risedronate or Alendronate is the correct intake. Bioavailability of oral bisphosphonates is poor due to low intestinal absorption rates [51] . The correct intake of a poorly absorbed bisphosphonate tablet is even more important if it is only given once per week. Food, calcium and other polyvalent cations can further decrease the absorption of these drugs, due to complex formation [52] . To ensure unimpaired intestinal absorption, correct intake of the bisphosphonate on an empty stomach in upright position early in the morning with a glass of tap water and avoidance of any other beverage, food or medicines at least 1/2 an hour thereafter is required for Risedronate and Alendronate. Noncompliance with these instructions may lead to a lower absorption of the bisphosphonate with a risk of impaired treatment outcome. The risk of mistakes and reduced compliance when treating osteoporosis with a weekly oral bisphosphonate may be enlarged by frequent changes of prescribed or dispended bisphosphonates often without physicians not having the time to explain the reasons appropriately. Frequent changes of prescribed or dispended bisphosphonates, especially generic Alendronate tablets and packages, could lead to a complexity of therapy and a less good understanding of the regimen and thereby decrease the chance of a correct and eVective medication. Therefore, the likelihood to meet therapeutic goals of the therapy can be decreased.
Smaller increases in BMD due to lower persistence as a consequence of additional psychological factors There could exist other additional factors that may explain diVerences in compliance and persistence and, therefore, eYcacy. It cannot be excluded that besides adverse events psychological factors may also contribute to a reduced persistence with generic alendronates. The knowledge about being treated with generics may have an inXuence on patients' behavior. The perception of receiving a cheap or "second choice" medication may considerably reduce the acceptance and compliance in individual patients. Also in the above-cited Canadian study looking for gastrointestinal adverse events after switching from branded Alendronate to generic Alendronate, there were signiWcantly more adverse events during the second treatment phase although the patients were unaware of having been switched to generics [30] .
Study limitations
The present retrospective single center-study under practical real life conditions has a few limitations mainly due to the way data have been collected. As with all observational studies, systematic errors (e.g., selection bias) may be the basis for the observed results [53] . On the other hand, in our study there were no statistical diVerences in measurable patient characteristics among the three cohorts of patients at initiation of therapy. The strength of this study is that all interviews regarding compliance and persistence were conducted by one interviewer using a standardized semi-structured questionnaire designed to analyze a clearly study outcome. However, this design has limitations. As a survey, it evaluates a patient's level of present understanding of the dosing instructions, compliance, and persistence but cannot truly represent the respondent's previous behavior in taking the medication. Given that the long-term treatment goal is to improve adherence with bisphosphonates, randomization of women to either branded or Generic bisphosphonates with assessment of adherence would be an improved design for future clinical prospective studies. The strength of observational studies can be the generalizability of results. In contrast, the generalizability of results from randomized trials to a real world setting can be limited by diVerences between the two in relation to expertise of health care provider, quality of medical care, course of therapy, and types of patients [54] . For example, it has been observed that the majority of patients considered candidates for osteoporosis therapy by their physician would not meet the eligibility criteria for inclusion in the randomized trials [55] .
Summary and conclusions
SigniWcantly lower increases of lumbar spine and total hip BMD with generic alendronate once weekly as compared to the two branded originals (Fosamax ® , Actonel ® ) were observed. The reasons for the 40-50% lower BMD increased rates when using the generic compounds are not known yet. At least in part the lower eYcacy can be explained by a signiWcantly lower degree of persistence with generic alendronate, which could be related to a higher incidence of gastrointestinal adverse events. Other reasons could be lower bioavailability or potency of generic alendronate. We conclude from our study results that in daily practice there may be a high risk of a relatively reduced compliance with generic alendronate as compared to the original branded once weekly bisphosphonate tablets. This may considerably impair therapeutic outcomes and from a health economic point of view the lower price of generic alendronate will be no longer an advantage. Further studies to prove the possible risk of a reduced therapeutic eVectiveness when prescribing generic alendronate are urgently needed. 
